We have constructed a retroviral bicistronic vector, MFG/GID, that transduces the expression of both the A3 isoform of the rat glutathione S-transferase (GST A3), and the tyr-22 variant of the human dihydrofolate reductase (DHFR L22Y ). Transduction of murine 3T3 fibroblasts with this vector increased their in vitro resistance to chlorambucil (1.8-fold) and trimetrexate (TMTX) (748-fold). TMTX selection of a mixed population of 20% GID-transduced NIH 3T3 cells and 80% control cells resulted in a marked increase in the GST peroxidase activity associated with the GST A3 isoform (17.7-fold). MFG/GID-transduced primary clonogenic murine hematopoietic progenitor cells were likewise more resistant to TMTX and chlorambucil than control b-gal-transduced cells. Selecting GID-transduced hematopoietic cells with a combination of TMTX and a nucleoside transport inhibitor resulted in a marked increase in resistance upon re-exposure to TMTX (99% survival). Similarly, GID-transduced hematopoietic cells selected with TMTX were more resistant to chlorambucil, with 40% survival at a drug concentration that killed practically all control cells. These results suggest that antifolate-mediated selection of MFG/GID-transduced hematopoietic cells could be used as a mean to enrich the population of transduced cells prior to or following transplantation, thus potentially conferring in vivo chemoprotection to nitrogen mustards and antifolates.
O ne of the main limitations of cancer chemotherapy is the dose-related systemic cytotoxicity of antineoplastic agents, predominantly the myelosupression. Conferring chemoprotection to hematopoietic cells through retrovirus gene transfer of drug resistance genes might decrease the principal dose-limiting toxicity of anticancer chemotherapy. This strategy has been validated in animal models of gene transfer using multidrug resistance 1 (MDR1), [1] [2] [3] multidrug resistance-associated protein 1 (MRP-1), 4 dihydrofolate reductase (DHFR), 5, 6 glutathione-S-transferase-p, 7 methylguanine methyltransferase, 8, 9 and bacterial alkyltransferases. 10 We have been investigating the potential use of the rat A3 isoform of glutathione-S-transferase (GST A3) in conferring protection against alkylating drugs such as chlorambucil and mechlorethamine. Alkylating drugs are particularly relevant to strategies of chemoprotection because they are active against a wide range of tumor types. Alkylating drugs are also commonly included in dose intensification regimens given their steep doseresponse curve in tumor cell kill. The GST A3-A3 homodimer is a member of the GST alpha isoform family, related to the GST superfamily of homo-and heterodimer detoxifying enzymes, which catalyze the conjugation of glutathione (GSH) to a variety of xenobiotics and cellular metabolites. GSTs substrates are generally highly hydrophobic molecules with electrophilic centers that can undergo GST-mediated GSH nucleophilic substitution, addition, or reduction. GSH conjugates are finally disposed of by excretion via the ATP-driven efflux pumps MRP-1 and MRP-2. 11, 12 Overexpression of the enzymes of the GST alpha family, characterized by a high peroxidase activity, 13 has been associated with alkylator resistance in colon cancer, 14 lymphocytic and myelogenous leukemia, 15, 16 gastric cancer, 17 mammary carcinoma, 18, 19 prostate cancer, 20 and other malignancies, as reviewed by Raha and Tew. 21 Direct demonstration of the role of GST in drug resistance was achieved by transfecting the GST cDNA (alpha, mu, or pi) into eucaryotic cells. [22] [23] [24] [25] GST overexpression was also found to correlate with the inhibition of DNA crosslink formation. 22 We have previously shown that human K-562 cells, murine NIH 3T3 fibroblasts, and primary murine hematopoietic progenitor cells developed increased in vitro resistance to nitrogen mustards following GST A3-retrovirus-mediated gene transfer. 26, 27 However, we were previously unable to demonstrate a decrease in alkylatorinduced leukopenia in mice following transplantation with bone marrow cells (BMCs) transduced with a GST A3 retroviral vector (Cournoyer et al, unpublished data). Given that only 10-20% of the hematopoietic cells were genetically modified in these animals, it is most likely that the efficiency of transduction was insufficient to impact on alkylator-induced hematotoxicity. 28 Using a DHFR vector, other investigators have observed that a transduction rate of at least 30% was required in hematopoietic cells to confer significant chemoprotection. 29 Likewise, the failure to achieve a significant level of hematopoietic chemoprotection in clinical trials using MDR1 vectors appears to have been related to the low efficiency of gene transfer in primitive human hematopoietic cells. [30] [31] [32] [33] In principle, the proportion of retrovirally transduced cells could be increased through either an improved efficiency of gene transfer, or through positive enrichment for genetically modified cells. Selection strategies combining DHFR-containing bicistronic vectors and selection with an antifolate-based regimen have been shown to increase significantly the percentage of vector-expressing cells, both in vitro [34] [35] [36] and in vivo. [37] [38] [39] Secondary transplant of transduced hematopoietic cells further demonstrated that, under appropriate conditions, the selection exerted by antifolate drugs occurred at the level of primitive hematopoietic stem cells. 38, 39 Here, we constructed a retroviral bicistronic vector that includes the cDNAs of the A3 isoform of the rat GST and the tyr-22 variant of DHFR (DHFR L22Y ): MFG/GSTA3-IRES-DHFR L22Y (MFG/GID). In this type of bicistronic vectors, cap-independent translation of the downstream gene is initiated by an internal ribosome entry site (IRES). [40] [41] [42] [43] This L22Y variant of DHFR was selected since it was originally established to confer the maximal TMTX resistance in fibroblasts. 6 Murine fibroblasts transduced with MFG/GID were found to be resistant to antifolates as well as alkylating agents. MFG/GIDtransduced fibroblasts could be selected, either with melphalan or with trimetrexate (TMTX), resulting in increased resistance to alkylating drugs and/or increased expression of GST A3-associated GSH peroxidase activity. Transduced murine hematopoietic progenitor cells likewise displayed increased resistance to TMTX and chlorambucil. Selection of transduced hematopoietic cells with a combination of TMTX and a nucleoside transporter inhibitor further increased their resistance to both the drugs. Our results suggest that antifolate-mediated selection of MFG/GID-transduced hematopoietic cells could be used as a means to enrich the population of transduced cells prior to or following transplantation, thus, potentially conferring in vivo chemoprotection to nitrogen mustards and antifolates.
Materials and methods

Cell culture and drug selection
The retrovirus packaging cell lines GP+E86 and GP+en-vAM12, as well as the NIH 3T3 mouse fibroblast cell line were cultured in Dulbecco's modified Eagle's medium (DMEM, GibcoBRL, Burlington, Canada) supplemented with 10% fetal bovine serum (FBS) (heat-inactivated) and gentamycin (5 mg/ml) in 5% CO 2 at 371C with constant humidity. Melphalan, chlorambucil, and nitrobenzylmercaptopurine riboside (NBMPR) were obtained from Sigma-Aldrich Canada, Oakville, Ont., Canada. Trimetrexate glucuronate (TMTX, Neutrexin s ) was obtained from US Bioscience, West Conshohocken, PA.
Vector constructs
The MFG/GSTA3-IRES-DHFR L22Y vector (MFG/GID) contains the rat A3 isoform of GST cDNA, followed by the IRES of the encephalomyocarditis virus, and by the cDNA of a mutated form of DHFR, where the leucine at position 22 was substituted by tyrosine (Fig 1) . The Figure 1 Schematic representation of the retroviral vector constructions, based on the Moloney-murine leukemia virus. The MFG/GID vector includes the cDNA of the A3 isoform of the rat GST A3 and the leucine to tyrosine-22 variant of DHFR cDNA (DHFR L22Y ). The DHFR L22Y cDNA is preceded by an IRES, thus permitting capindependent translation of the DHFR gene. The expression of both the genes is regulated by viral elements of the 5 0 -long terminal repeat (LTR). MFG/GST and MFG/b-gal are monocistronic vectors including, respectively, the GST A3 cDNA and the b-galactosidase cDNA inserted into MFG-vector backbone. This figure is not drawn to scale.
Selection of GST/DHFR-transduced cells J-P Belzile et al IRES-DHFR L22Y fragment was released from the emc22Ypcr vector 44 (kindly provided by Dr Jacques Galipeau) by XhoI and NotI digestion, and blunt-end ligated into pBluescript/3 0 MFG-GST linearized at its NotI site. The construction of pBluescript/3 0 MFG-GST, which contains a fragment of the MFG vector sequence, was previously described. 45 The 3 0 MFG-GSTA3-IRES-DHFR L22Y fragment was released from the pBluescript plasmid by digestion with AgeI and BamHI, and ligated between the same sites into the MFG vector (obtained from R Mulligan, Whitehead Institute, Cambridge, MA). The construction of MFG/GST and MFG/lac-Z was previously described. 45 , 46 
Southern blot analysis
The general procedure for Southern blotting was the same as described previously. 45 A measure of 10 mg of genomic DNA from different cell lines was digested with NheI, run on a 1% agarose gel and finally transferred to a nylon membrane. Graded quantities of NheI-digested pMFG/ GST and pMFG/GID plasmids, supplemented with 10 mg of NIH 3T3 genomic DNA, were used to provide a copy number/cell standard. The 611 bp GST probe was generated by digestion of pMFG/GST with PflMI and SacII, and radio-labeled by random primer labeling. The DHFR probe was obtained by random-primer radiolabeling of the 330 bp NcoI-AccI fragment released from the emc22Ypcr plasmid.
Virus-producing cells and NIH 3T3-derived cell lines
The plasmid pMFG/GID was cotransfected in a 10:1 molar ratio with pSV2neo 47 into GP+E-86 ecotropic retroviral packaging cells using a liposomal formulation of the polycationic lipids DOTMA and DOPE (Lipofectin s , GibcoBRL, Burlington, Canada). Stable transfected clones were selected for 21 days with G418 (Geneticin s , GibcoBRL, Burlington, Canada) at a concentration of 300 mg/ml. GP+envAM12 amphotropic packaging cells were cocultivated for 10 days with stable ecotropic producers (GP+E-86/GID) in the presence of 4 mg/ml polybrene (Sigma-Aldrich Canada, Oakville, Canada) and finally selected with 200 mg/ml hygromycin (SigmaAldrich Canada, Oakville, Canada). GP+E86 ecotropic packaging cells were exposed daily for 15 days to 45-mmfiltered medium that contained virus produced by a polyclonal population of amphotropic virus-producing cells (GP+envAm12/GID), in presence of 4 mg/ml polybrene. 48 The GP+E-86/b-gal and GP+E-86/DHFR ecotropic virus-producing cell lines were constructed in the same way using, respectively, the MFG/lac-Z and the HaL22Y 6 vectors. The virus titer of virus-producing cells was determined in a clonogenic assay by selecting transduced clones with TMTX for the GP+E-86/GID cell line (titer ¼ 1.2 Â 10 5 CFU/ml), or by staining with Xgal for the GP+E-86/b-gal cell line (titer ¼ 8 Â 10 4 CFU/ ml). NIH/GID, NIH/GST, and NIH/DHFR were produced by exposing the NIH 3T3 cells to filtered medium from, respectively, GP+envAM12/GID, GP+envAM12/ GST, 45 and GP+envAM12/DHFR, daily for 3 consecutive days, in presence of 4 mg/ml polybrene.
MTT cytotoxicity assay and GST-peroxidase assay
The procedures for MTT and GST-peroxidase assays were as previously described. 45 Retrovirus-mediated transduction of hematopoietic cells and drug selection C3H/HeJ syngenic mice (Jackson Lab, Bar Harbour, ME) were housed in a conventional animal facility and were used between 10 and 18 weeks of age. BMCs were harvested from the hind leg femurs and tibias of C3H/HeJ donors treated intraperitoneally with 150 mg/kg 5-fluorouracil 48 hours prior to marrow collection. BMC were prestimulated for 48 hours in alpha minimum essential medium (GibcoBRL, Burlington, Canada) supplemented with 20% FBS, 20 ng/ml murine recombinant interleukine-3 (IL-3), 50 ng/ml murine recombinant interleukine-6 (IL-6), 100 ng/ml murine recombinant stem cell factor, and 5 mg/ml gentamycin (GibcoBRL, Burlington, Canada). At 24 hours prior to transduction, GP+E-86/GID and GP+E-86/b-gal cells were irradiated (20 Gy) and plated at a density of 5 Â 10 6 cells/80 cm 2 . Five million nucleated nonadherent BMCs were transferred from the prestimulation flasks and cocultivated with virus-producing cells. Cocultures were incubated for 48 hours under the same conditions used for the prestimulation, with the addition of 8 mg/ml polybrene. Nonadherent BMCs were then harvested from the cocultures and cultivated in the presence of 50 nM TMTX and 1 mM NBMPR for 96 hours in the same medium described above. In this case, the FBS was pretreated with 1 U/ml thymidine phosphorylase for 4 hours, at 371C, to allow for selection with antifolate drugs. Nonselected bone marrow cells were kept in culture for 96 hours under the same conditions, but without TMTX or NBMPR.
Colony-forming unit in culture (CFU-C) assay
Transduced nucleated BMCs, selected or not with TMTX and NBMPR, were collected and plated at a density of 1 Â 10 5 cells/ml in 0.9% methylcellulose in alpha-MEM (Stem Cell Technologies, Vancouver, BC, Canada) supplemented with 30% FBS, 1% bovine serum albumin (Sigma-Aldrich Canada, Oakville, Canada), 2% pokeweed murine spleen cells-conditioned medium (Stem Cell Technologies, Vancouver, BC, Canada), 10 À4 M mercaptoethanol and 2 mM glutamine for 10-14 days. In the case of assays with TMTX, the FBS was pretreated with 1 U/ml thymidine phosphorylase for 4 hours at 371C. The level of drug resistance was determined by scoring the percentage of colonies of 50 cells or more (granulocytes, macrophages, or granulocytes and macrophages) surviving in the presence of the drug.
Transduction efficiency
The transduction rates in hematopoietic cells were determined by PCR amplification from individual CFU-C using the sense primer 5 0 CCATCCTCTAGACT-GCCATGCCGGG 3 0 and the antisense primer 5 0 CCCCATCCGCGGTTAACTGAAG-ATCTTAA 3 0 ; the underlined sequence corresponds to the MFG sequence preceding the initiation codon of GST A3, and the antisense primer anneals to the 3 0 end of the cDNA of GST A3. 45 
Results
Integrity of the transduced retroviral construct
The integrity of the vector construct transduced in various cell lines was evaluated by Southern blot. Genomic DNA from the tested cell lines was digested with NheI, which cuts twice in the MFG vector backbone sequence. This resulted in the generation of fragments of predictable sizes, independently of the site of the vector integration in the host cell genome. Figure 2a shows the GST A3-containing fragments of 2721 bp generated from MFG/ GST-transduced NIH 3T3 fibroblasts, and the 3940 bp generated from MFG/GID-transduced NIH 3T3 and GP+envAM12 cells. Figure 2b shows the DHFRcontaining 6300 bp fragment generated from NIH/DHFR and A/DHFR cells, and the 3940 bp fragment generated from MFG/GID-transduced cell lines. An approximate average copy number per cell was determined by comparing the computer-assisted densitometry analysis of each fragment digested from genomic DNA to that of standards consisting of graded amounts of pMFG/GST or pMFG/GID mixed with NIH 3T3 genomic DNA and digested with NheI. The average MFG/GID copy number for NIH/GID was determined to be approximately 1 copy/cell. Following selection with 25 mM melphalan, the average copy number per cell of NIH/GID increased to approximately two copies/cell. TMTX selection did not affect the average copy number of vectors in NIH/GID nor NIH/DHFR cells. The MFG/GID average copy number of the polyclonal amphotropic GP+envAM12/ GID virus producers ranged between approximately 7 (as estimated with the DHFR probe) and 10 copies (GST probe) per cell.
Peroxidase enzyme activities of GST-transduced NIH 3T3 fibroblasts
Cytosolic extracts from cells transduced with the MFG/ GST or MFG/GID vectors were analyzed for their GSH peroxidase activity, which is associated with the expression of GST A3. The polyclonal population of NIH/GID cells showed a 700-fold increase in peroxidase activity (7.21 U) compared to the original NIH 3T3 cell line (Po.05) ( Table 1) . Although higher levels of peroxidase activity were observed in NIH 3T3 cells transduced with the monocistronic vector MFG/GST, selection of NIH/ GID with 15-25 mM melphalan further increased the peroxidase activity to levels comparable to that of melphalan-selected NIH/GST cells (450 U). NIH/GID cells selected with up to 250 nM TMTX did not display any significant increase in the peroxidase activity. Given that a low copy number of the mutant DHFR L22Y gene had been found to be sufficient to confer high level of resistance to TMTX (see below), we evaluated whether the apparent failure to select NIH/GID with TMTX was due to the fact that a majority of 3T3 cells were transduced and were not subject to further selection with TMTX. We thus applied the TMTX selection to a mixed cell population comprised of 20% NIH/GID and 80% parent NIH 3T3 cells. In these conditions, TMTX selection indeed resulted in a 17.7-fold increase in peroxidase activity (from 0.72 to 12.74 U, Po.01).
Drug sensitivity assay
The drug sensitivity of transduced cells was determined by the MTT cytotoxicity assay (Fig 3) . The level of drug sensitivity is expressed as the inhibitory concentration- 50 ), the concentration of drug that inhibits cell growth by 50%. In this assay, NIH/GID cells displayed a 1.81-fold increase in resistance to chlorambucil compared with the parental NIH 3T3 fibroblast cell line (IC 50 
50% (IC
CFU-C assays of GID-transduced BMCs
CFU-C assays were performed to evaluate the effect of GID-transduction and antifolate selection on hematopoietic cells drug resistance. Primary murine hematopoietic cells were transduced by cocultivation with cells producing the retroviral vectors MFG/GID or MFG/bgal. A portion of the GID-transduced BMCs was then selected for 4 days with 50 nm TMTX and 1 mM NBMPR, whereas nonselected GID-and b-gal-transduced cells were kept in culture for the same duration without drug selection. BMCs were finally plated in colony assays in presence or not of TMTX or chlorambucil, and colonies were scored after 10-14 days. In total, 42% of 
Po.05 for the differences with GID-transduced, nonselected NIH 3T3 cells (unpaired Student's t-test).
Figure 3
The drug sensitivity of each cell line was determined by the MTT colorimetric assay and was expressed as the drug concentration required to inhibit cell growth to 50% of baseline (IC 50 ). Cells were platted at a density of 5000/well in 96-well plates and incubated for 3 days with a gradient of drug concentration. Results are the means of five independent assays, with 10 measurements in each assay, with standard error bars. The abbreviations used for the cell lines are the same as in Figure 1 . a: Po.05 for the differences with NIH 3T3 cells (unpaired Student's t-test) b: Po.005 for the differences with nonselected NIH/GID cells (unpaired Student's ttest).
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GID-transduced CFU-Cs survived in 50 nM TMTX, in comparison to 7% survival in MFG/b-gal-transduced cells (Fig 4a) . Selection of GID-transduced hematopoietic cells with TMTX and NBMPR increased their survival to 99% upon re-exposure to 50 nM TMTX, that is, a greater than two-fold increase in resistance compared to the nonselected cells (Po.0001). Thus, following TMTX selection there was an approximately 14-fold overall increase in TMTX resistance compared to b-gal-transduced cells (Po.0001). Transduced hematopoietic cells were also tested for their resistance to chlorambucil by subjecting them to graded concentration of the drug (Fig  4b) . GID-transduced colony-forming progenitor cells were more resistant to chlorambucil than control b-galtransduced cells at chlorambucil concentrations ranging from 5 Â 10 À6 to 5 Â 10 À4 M (Po.05 at all dose concentrations tested except at 1 Â 10 À4 M). Antifolate selection was found to further increase the resistance to chlorambucil by 1.4-2.9-fold at all concentrations tested (Po.05). The overall increase in resistance to chlorambucil of TMTX/NBMPR selected GID-transduced hematopoietic cells, in comparison with control b-gal-transduced cells, thus ranged from 1.7-to 22-fold at the concentrations tested (Po.05). PCR amplification of a vectorspecific sequence from genomic DNA extracted from individual hematopietic colonies also demonstrated that selection with TMTX and NBMPR increased the proportion of GID-transduced CFU-Cs from 70 to 90% (data not shown).
Discussion
We have previously reported that retroviral transduction of human myelogenous leukemia cells, murine fibroblasts, and bone marrow-derived hematopoietic progenitors with the cDNA of the rat A3 isoform of GST conferred an increased resistance to nitrogen mustards, such as chlorambucil and melphalan. 26, 27 However, we did not observe less severe chlorambucil-induced leukopenia in mice transplanted with GST-transduced BMCs. We also found that only 10-20% of the spleen and bone marrow-derived hematopoietic progenitor cells were vector-transduced at the time of sacrifice, 6 months post-transplantation, suggesting that the proportion of transduced cells was insufficient to obtain a protective effect against chlorambucil (Cournoyer et al, unpublished data). Studies of chemoprotection using DHFR mutants indicate that even when expressing cDNAs that confer a high level of protection, a transduction rate of 30% in myeloid progenitor cells is necessary to confer a significant level of chemoprotection. 29 Oncoretroviral vectors such as the one used in this study (Moloney murine leukemia virus) can only access the host chromatin when the nuclear membrane breaks down during mitosis. 49 Retroviral integration in hematopoietic stem cells, which are predominant in a nondividing quiescent state, is thus greatly impaired. Some have proposed to use lentiviral vectors based on the human or simian lentiviruses to increase the transduction efficiency in hematopoietic stem cells (HSCs). Lentiviral vectors, through their gag and accessory proteins, have the ability to penetrate the intact nucleus through nuclear pores, and consequently do not require an actively dividing cellular host. [50] [51] [52] Furthermore, it has been shown in a mouse model that lentiviral vectors can efficiently transduce human HSCs in the absence of cytokines. 53 While the use of lentiviral vectors remains an attractive strategy, safety concerns over their eventual use in clinical trials still exist.
An alternate strategy to increase the proportion of transduced HSCs in vivo would be to enrich selectively the transduced cells. This can be accomplished by incorporating the expression of drug resistance genes or cell surface molecules in the retroviral vector. Although we have shown that GST A3 is a selectable marker, selection with nitrogen mustard derivatives would not be attractive because of the risk of long-term mutagenic damages related to the formation of DNA crosslinks and protein Selection of GST/DHFR-transduced cells J-P Belzile et al adducts. Several groups investigated the potential use of the MDR1-encoded P-glycoprotein as a selectable marker in bicistronic retroviral vectors. Initial studies were hampered by the presence of cryptic splice sites in the MDR1 cDNA, which lead to vector instability and rearrangement. 1 Re-engineered versions of MDR1 vectors have corrected this defect, 44 but overexpression of functional P-glycoprotein in HSCs produced anomalies in their cell cycle, possibly related to an antiapoptotic effect. Mice transplanted with MDR1-transduced HSCs thus developed a myeloproliferative syndrome. 54, 55 This myeloproliferative syndrome was, however, not observed in rhesus monkeys transplanted with MDR1-transduced cells, although this study only encompassed a small number of specimens. 56 Given that the mechanism underlying the antiapoptotic effect of the P-glycoprotein pump remains unknown, it is plausible that overexpression of other transporters of the ABC family might have a similar adverse effect on cell proliferation.
Another gene that has been used as a selectable marker in bicistronic vector is the enzyme DHFR. Mutations at amino acids 22 and 31 of DHFR, two critical sites for substrate binding, have produced variants that are highly resistant to the folate analogs MTX and TMTX. 57, 58 These mutants were shown to protect HSCs in vivo against high doses of antifolate drugs. 5, 6 Enrichment of DHFR-transduced hematopoietic cells with antifolate treatment was demonstrated both in vitro [34] [35] [36] and in vivo. [37] [38] [39] Selection significantly increased the percentage of vector-expressing peripheral blood erythrocytes, platelets, granulocytes, and T and B lymphocytes. In addition, secondary transplant experiments demonstrated that selection occurred at the level of HSCs. 39 An antifolateresistant mutant DHFR was thus likely to be an efficient selectable marker to increase the proportion of GSTtransduced HSCs.
In the present study, we constructed a bicistronic vector (MFG/GID) expressing GST A3 and the L22Y variant of DHFR, which was originally shown to display the highest resistance to TMTX in fibroblasts. 6 The integrity of the MFG/GID vector into transduced cells was assessed by Southern blot (Fig 2) . This showed that the majority of the polyclonal GP+envAM12/GID virus-producing cells contained the expected full-length copy of the GID vector. The functional expression of both transduced genes was determined by an increase in peroxidase activity, and an increase in resistance to both nitrogen mustards and antifolates (Figs 2 and 3) . GID-transduced 3T3 cells showed an increased resistance to chlorambucil (1.81-fold) and TMTX (748-fold), but were not significantly more resistant to melphalan. These results suggest that MFG/GID confers a high resistance to antifolates and a moderate increase in resistance to nitrogen mustards. Furthermore, selection of GID-transduced cells with melphalan increased both the GST peroxidase activity and the resistance to chlorambucil, melphalan, and TMTX. However, selection with TMTX, even at high concentrations (500 nM), failed to further increase the GST peroxidase activity, or the resistance to either class of drugs when it was applied to a population of GIDtransduced NIH 3T3 cells with an average copy number of one vector per cell. While NIH/GID selected with melphalan displayed an increase of the vector copy number per cell, selection with TMTX did not affect the vector copy number. In contrast, TMTX selection of a mixed population of 20% GID-transduced 3T3 cells and 80% control cells resulted in increased GST peroxidase activity (18-fold) . This indicates that a single functional copy of the DHFR L22Y gene is sufficient to confer a high level of resistance to TMTX. Thus, DHFR L22Y -transduced cells with a single functional copy of the vector cannot be selected further. Nonetheless, TMTX selection could potentially be an effective strategy for enrichment of transduced hematopoietic cells, since the goal is to enrich a minority of transduced stem cells among a larger population of nontransduced cells.
We then proceeded to verify the drug resistance properties of our MFG/GID vector in bone marrowderived CFU-Cs. Transduction of BMCs was performed by coculture with either GP+E-86/GID or GP+E-86/bgal (control) ecotropic virus-producing cells. A combination of TMTX and the nucleoside transport inhibitor NBMPR was used to select in vitro transduced BMCs. It has been shown that the antifolate methotrexate (MTX) was ineffective against generally quiescent HSCs. The reduced folate carrier 1 (RFC1), by which MTX mainly enters the cell, is generally inactive in quiescent HSCs and this results in a heightened tolerance to MTX. [59] [60] [61] The nonclassical antifolate TMTX, which diffuses passively into the cell, has been devised to increase the toxicity of stem cells to antifolates. It has, however, been demonstrated that a nucleoside transporter inhibitor in conjunction with TMTX would be necessary to attain a high degree of toxicity, 62, 63 since cells compensate for the inhibitory effects of TMTX through activation of RFCs 60 and nucleoside transporters such as the es transporters and sodium-dependent transporters. 64, 65 Survival in 50 nM TMTX of selected GID-transduced CFU-Cs was compared with the survival of nonselected GID-and bgal-transduced CFU-Cs (Fig 4a) . We observed that GID-CFU-Cs were more resistant to 50 nM TMTX (42.2% of survival) compared to the control CFU-Cs (7.0% of survival). Selection of GID-CFU-Cs, as described above, resulted in a high degree of resistance to TMTX (99.3%), suggesting that selection with 50 nM TMTX and 1 mM NBMPR was particularly effective. Consequently, we also showed that selection increased the percentage of GIDtransduced CFU-Cs from 70 to 90%, as determined by PCR analysis of CFU-Cs colonies. To determine if selection would also elevate chlorambucil resistance, transduced CFU-Cs, selected or not, were subjected to a gradient of chlorambucil on a methylcellulose-based medium and their survival rates were scored (Fig 4b) . Selected CFU-Cs were significantly more resistant to chlorambucil, compared with nonselected and control CFU-Cs, for concentrations of 5 Â 10 À6 to 5 Â 10 À4 M. These results imply that antifolate selection of GIDtransduced bone marrow-derived hematopoietic cells is an efficient strategy to increase the resistance to both antifolates and nitrogen mustards and that it could be used to enrich ex vivo or in vivo the proportion of transduced cells in transplanted mice.
Retroviral vectors expressing genes that confer resistance to different types of antineoplastic and myelosupressive drugs are of particular relevance to cancer treatment, since combination drug therapy is a common practice to increase tumour growth inhibition and to suppress disseminated metastastic cancerous cells. The combined expression of GST A3 and DHFR L22Y in a patient's hematopoietic cells could increase the tolerance to both nitrogen mustard-derived drugs and antifolates such as MTX, potentially reducing the severity of cytopenia (neutropenia, leukopenia, anemia) and thus improving the quality of life of patients undergoing chemotherapy. In addition, GID-mediated chemoprotection could lead to an intensification of drug treatment, by reducing the myelosuppressive effects of nitrogen mustards, to better suppress tumor growth and thus enhance the prognosis of chemoresponsive cancers. Moreover, nitrogen mustard treatments, and specifically mechlorethamine, have been associated with an increased risk of developing secondary acute nonlymphoblastic leukemia 66, 67 and acute lymphoblastic leukemia. 67 A higher hematopoietic tolerance to alkylating agents could potentially attenuate DNA-crosslink formation and thus reduce the risk of secondary leukemia in patients who have received repeated alkylating drug treatments.
In conclusion, we showed that murine 3T3 fibroblasts and bone marrow-derived hematopoietic progenitors transduced with MFG/GID were resistant to antifolates and nitrogen mustards. We have also demonstrated that in vitro selection of GID-transduced murine hematopoietic cells with a combination of TMTX and NBMPR further increased the resistance of CFU-Cs to chlorambucil and TMTX, reinforcing the established effectiveness of DHFR/TMTX/NBMPR enrichment of hematopoietic cells. 39 Future work will concentrate on conferring nitrogen mustard hematopoietic chemoprotection following selection of transduced cells in transplanted mice. This work has significant clinical implications given the broad antitumor activity of nitrogen mustards.
